Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Fig. 2

Each vertical bar represents the maximum change obtained for a single patient, identified by the six digit code at the bottom of the graph, that had a baseline CT scan and at least one subsequent scan. The horizontal dotted line at 50% represents a cut-off above which lymph node enlargement represents progressive disease whereas the horizontal dotted line at − 30% represent a cut-off below which lymph node regression represents clinically significant improvement. Patient 107–602 (500 mg/m2 cohort) did not have a post-dose CT scan and was not evaluable

Back to article page